Year |
Citation |
Score |
2015 |
Labidi-Galy SI, Clauss A, Ng V, Duraisamy S, Elias KM, Piao HY, Bilal E, Davidowitz RA, Lu Y, Badalian-Very G, Györffy B, Kang UB, Ficarro S, Ganesan S, Mills GB, et al. Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors. Oncogene. 34: 373-83. PMID 24469047 DOI: 10.1038/Onc.2013.562 |
0.577 |
|
2014 |
Davidowitz RA, Selfors LM, Iwanicki MP, Elias KM, Karst A, Piao H, Ince TA, Drage MG, Dering J, Konecny GE, Matulonis U, Mills GB, Slamon DJ, Drapkin R, Brugge JS. Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. The Journal of Clinical Investigation. 124: 2611-25. PMID 24762435 DOI: 10.1172/Jci69815 |
0.744 |
|
2013 |
Labidi-Galy I, Clauss A, Ng V, Duraisamy S, Elias KM, Bilal E, Davidowitz RA, Lu Y, Badalian-Very G, Piao H, Kang U, Ficarro S, Ganesan S, Mills GB, Marto J, et al. Abstract B74: Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors Clinical Cancer Research. 19. DOI: 10.1158/1078-0432.Ovca13-B74 |
0.6 |
|
2012 |
Davidowitz RA, Iwanicki MP, Brugge JS. In vitro mesothelial clearance assay that models the early steps of ovarian cancer metastasis. Journal of Visualized Experiments : Jove. PMID 22371143 DOI: 10.3791/3888 |
0.746 |
|
2011 |
Iwanicki MP, Davidowitz RA, Ng MR, Besser A, Muranen T, Merritt M, Danuser G, Ince TA, Ince T, Brugge JS. Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Cancer Discovery. 1: 144-57. PMID 22303516 DOI: 10.1158/2159-8274.Cd-11-0010 |
0.46 |
|
2011 |
Davidowitz R, Iwanicki M, Selfors L, Konecny G, Dering J, Slamon D, Brugge J. Abstract 4751: Identification of mechanism involved in mesothelial clearance by ovarian tumor spheroids Cancer Research. 71: 4751-4751. DOI: 10.1158/1538-7445.Am2011-4751 |
0.735 |
|
Show low-probability matches. |